Actively Recruiting
Open-Label Extension Evaluating Long-Term Safety and Efficacy of Marstacimab Prophylaxis in Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Male Participants
Led by Pfizer · Updated on 2026-10-26
245
Participants Needed
78
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying long-term safety, tolerability, and effectiveness of marstacimab as a preventive treatment for severe hemophilia A and moderately severe to severe hemophilia B in participants who completed earlier Phase 3 studies without early termination. This open-label extension study involves male participants aged 1 to under 75 years with low coagulation factor activity, aiming to monitor marstacimabs impact over an extended period. Participants aged 12 years and older receive a 300 mg subcutaneous loading dose of marstacimab followed by 150 mg weekly injections, with dose escalation to 300 mg weekly if needed. Those aged 6 to under 12 years get an initial 150 mg loading dose followed by 75 mg weekly, with possible escalation to 150 mg weekly. All participants use a prefilled pen for administration, with a prefilled syringe available if needed or in regions where it is the commercial presentation. During the study, participants will be monitored for adverse events, serious adverse events, thrombotic events, injection site reactions, and laboratory changes over up to seven years. Researchers will also assess bleeding episodes, joint health, quality of life questionnaires, and coagulation factor consumption. Regular visits and evaluations will support long-term safety and efficacy monitoring throughout the study duration.
CONDITIONS
Brief Title
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here